





Disclosures


· Genentech- Scientific Advisory Board

























KRAS mutant adenocarcinoma


- Most prevalent oncogenic driver in lung adenocarcinoma
 - Occurs in 25% cases
 - · Mostly smokers, older patients
- Selumetinib plus docetaxel is the first clinically validated strategy for KRAS mutant NSCLC
 - Co-existing tumor suppressor mutations may matter: p53 vs. LKB1
- Prognostic significance?


Sons at all Jacont Oscal 2012






























































Wait, there's more...

- · Other mutation-specific antibodies
 - BRAF VE1
- Tumor suppressor genes- "predictive" IHC
 - PTEN
 - LKB1
- Resistance mechanisms- ALK and ROS1 targeted therapies
 - Role for re-biopsy?
- Immunotherapy
 - PDL1 IHC
 - Neoantigen burden

